HRP20010655B1 - Pyridopyranoazepine derivatives, preparation and therapeutic use - Google Patents

Pyridopyranoazepine derivatives, preparation and therapeutic use

Info

Publication number
HRP20010655B1
HRP20010655B1 HR960321A HRP20010655A HRP20010655B1 HR P20010655 B1 HRP20010655 B1 HR P20010655B1 HR 960321 A HR960321 A HR 960321A HR P20010655 A HRP20010655 A HR P20010655A HR P20010655 B1 HRP20010655 B1 HR P20010655B1
Authority
HR
Croatia
Prior art keywords
preparation
therapeutic use
pyridopyranoazepine
derivatives
pyridopyranoazepine derivatives
Prior art date
Application number
HR960321A
Other languages
English (en)
Inventor
Frederic Galli
Samir Jegham
Alistair Lochead
Axelle Samson
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HRP20010655A2 publication Critical patent/HRP20010655A2/hr
Publication of HRP20010655B1 publication Critical patent/HRP20010655B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HR960321A 1999-03-05 2001-09-05 Pyridopyranoazepine derivatives, preparation and therapeutic use HRP20010655B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9902784A FR2790474B1 (fr) 1999-03-05 1999-03-05 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
PCT/FR2000/000502 WO2000053608A1 (fr) 1999-03-05 2000-03-01 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
HRP20010655A2 HRP20010655A2 (en) 2002-08-31
HRP20010655B1 true HRP20010655B1 (en) 2003-06-30

Family

ID=9542888

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960321A HRP20010655B1 (en) 1999-03-05 2001-09-05 Pyridopyranoazepine derivatives, preparation and therapeutic use

Country Status (37)

Country Link
US (2) US6538003B1 (id)
EP (1) EP1161434B1 (id)
JP (1) JP4806123B2 (id)
KR (2) KR20070086359A (id)
CN (1) CN1137894C (id)
AR (1) AR022820A1 (id)
AT (1) ATE231869T1 (id)
AU (1) AU764625B2 (id)
BG (1) BG65211B1 (id)
BR (1) BR0008763A (id)
CA (1) CA2372063C (id)
CO (1) CO5160250A1 (id)
CZ (1) CZ302259B6 (id)
DE (1) DE60001307T2 (id)
DK (1) DK1161434T3 (id)
EE (1) EE04497B1 (id)
ES (1) ES2191611T3 (id)
FR (1) FR2790474B1 (id)
HK (1) HK1040398B (id)
HR (1) HRP20010655B1 (id)
HU (1) HU228671B1 (id)
ID (1) ID30116A (id)
IL (2) IL145150A0 (id)
MX (1) MXPA01008972A (id)
NO (1) NO327119B1 (id)
NZ (1) NZ513561A (id)
PE (1) PE20001543A1 (id)
PL (1) PL201683B1 (id)
RS (1) RS49997B (id)
RU (1) RU2238273C2 (id)
SK (1) SK284339B6 (id)
TR (1) TR200102403T2 (id)
TW (1) TWI222975B (id)
UA (1) UA61164C2 (id)
UY (1) UY26048A1 (id)
WO (1) WO2000053608A1 (id)
ZA (1) ZA200106811B (id)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
AU2003250106B2 (en) 2002-07-18 2009-11-26 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
JP4750421B2 (ja) * 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
US20090076059A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dianicline
CN101981027B (zh) * 2007-12-07 2014-08-06 Abbvie德国有限责任两合公司 氨基甲基取代的羟吲哚衍生物及其用于治疗加压素依赖性疾病的用途
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
WO2009071689A2 (de) * 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US9463190B2 (en) * 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
DK2355822T3 (da) 2008-11-19 2013-01-28 Envivo Pharmaceuticals Inc behandling af kognitive forstyrrelser med (R)-7-chlor-N-(quinuclidin-3-yl)benzoe[b]thiophen-2-carboxamid og farmaceutisk acceptable salte deraf
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
EP2435080A2 (en) * 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
ES2746850T3 (es) 2010-05-17 2020-03-09 Forum Pharmaceuticals Inc Formulaciones farmacéuticas que comprenden formas cristalinas de clorhidrato de (R)-7-cloro-N-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
EP0853621A1 (en) * 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
WO1998054189A1 (en) * 1997-05-30 1998-12-03 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
CO5160250A1 (es) 2002-05-30
HK1040398B (zh) 2003-07-18
HU228671B1 (en) 2013-05-28
PE20001543A1 (es) 2001-03-18
US6538003B1 (en) 2003-03-25
EP1161434A1 (fr) 2001-12-12
US20030187012A1 (en) 2003-10-02
CA2372063A1 (en) 2000-09-14
HRP20010655A2 (en) 2002-08-31
CA2372063C (en) 2011-01-11
KR20070086359A (ko) 2007-08-27
UA61164C2 (uk) 2003-11-17
CZ302259B6 (cs) 2011-01-19
CN1137894C (zh) 2004-02-11
SK12422001A3 (sk) 2002-04-04
RU2238273C2 (ru) 2004-10-20
PL201683B1 (pl) 2009-04-30
HUP0201753A2 (en) 2002-09-28
WO2000053608A1 (fr) 2000-09-14
RS49997B (sr) 2008-09-29
TWI222975B (en) 2004-11-01
NO327119B1 (no) 2009-04-27
EE04497B1 (et) 2005-06-15
JP4806123B2 (ja) 2011-11-02
CZ20013102A3 (cs) 2002-01-16
SK284339B6 (sk) 2005-02-04
ATE231869T1 (de) 2003-02-15
US6908927B2 (en) 2005-06-21
BG105828A (bg) 2002-03-29
KR20010102492A (ko) 2001-11-15
AU764625B2 (en) 2003-08-28
FR2790474A1 (fr) 2000-09-08
DK1161434T3 (da) 2003-05-26
ID30116A (id) 2001-11-08
ZA200106811B (en) 2002-08-19
TR200102403T2 (tr) 2001-12-21
YU59601A (sh) 2004-03-12
KR100768355B1 (ko) 2007-10-17
NO20014270L (no) 2001-11-05
NO20014270D0 (no) 2001-09-03
EE200100470A (et) 2002-12-16
AR022820A1 (es) 2002-09-04
AU2922600A (en) 2000-09-28
BG65211B1 (bg) 2007-07-31
UY26048A1 (es) 2000-09-29
HK1040398A1 (en) 2002-06-07
EP1161434B1 (fr) 2003-01-29
DE60001307T2 (de) 2003-12-11
FR2790474B1 (fr) 2001-04-06
IL145150A (en) 2007-06-03
NZ513561A (en) 2003-06-30
IL145150A0 (en) 2002-06-30
HUP0201753A3 (en) 2004-12-28
DE60001307D1 (de) 2003-03-06
PL352330A1 (en) 2003-08-11
MXPA01008972A (es) 2002-03-27
JP2002539129A (ja) 2002-11-19
CN1343208A (zh) 2002-04-03
ES2191611T3 (es) 2003-09-16
BR0008763A (pt) 2002-01-02

Similar Documents

Publication Publication Date Title
HK1048999A1 (zh) 氮雜䓬吲衍生物，它們的製備和應用
HUP0401461A3 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
IL145150A0 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
HUP0202214A2 (en) Adamantane derivatives, preparation and use thereof
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
HUP0105039A3 (en) Fungicidal propargylether derivatives, preparation and use thereof
HU0002848D0 (en) Cyclobutene derivatives, their preparation and their therapeutic uses
IL135451A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
HUP0201810A3 (en) Sootepenseone and its derivatives, their preparation and use as medicament
HUP0203468A3 (en) Betha-d-5-thioxylose derivatives, preparation method and therapeutic use thereof
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
IL135452A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
HUP0202377A2 (en) N-substituted perhydrodiazines, preparation and use thereof
HK1065792A1 (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
AU3971800A (en) 2-alkoxy-cyclobutene-3,4-dione derivatives, preparation and therapeutic use thereof
AU2526001A (en) 2-phenyl-quinoline derivatives, preparation method and therapeutic use thereof
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
SI1161434T1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
SI1230252T1 (en) Beta-d-5-thioxylose derivatives, preparation method and therapeutic use
AU5522499A (en) 2-aminoethyl-quinoline derivatives, preparation and therapeutic use
AU3971300A (en) 2-aminoethyl-indole derivatives, their preparation and therapeutic use

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS, FR

ODRP Renewal fee for the maintenance of a patent

Payment date: 20140210

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20150301